Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pulmazole
- Development stage
- Phase 2
- Lead developer
- Pulmatrix
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Pulmazole (PUR1900) is an inhaled dry powder formulation of the triazole antifungal itraconazole, engineered using Pulmatrix's proprietary iSPERSE (inhaled Small Particles Easily Respirable and Emitted) technology. iSPERSE utilizes small, dense, and dispersible particles to ensure efficient delivery to the airways via a dry powder inhaler. The drug is primarily being developed for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma or cystic fibrosis. By delivering itraconazole directly to the site of fungal colonization in the lungs, Pulmazole aims to achieve therapeutic local concentrations while significantly reducing systemic exposure. This approach is intended to mitigate the risks of systemic toxicities and complex drug-drug interactions (mediated by CYP3A4 inhibition) typically associated with oral itraconazole therapy. The mechanism of action involves the inhibition of fungal lanosterol 14-alpha-demethylase (CYP51), which prevents the conversion of lanosterol to ergosterol, thereby compromising fungal cell membrane integrity and inhibiting growth.
- Brand names
- Pulmazole
- Other names
- Inhaled itraconazole
02
Targets
CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on Pulmazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pulmazole.